Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Creators
- 1. Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, 304 60 Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 304 60 Pilsen, Czech Republic.
- 2. Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, 304 60 Pilsen, Czech Republic.
- 3. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 4. Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 5. Department of Oncology, University Hospital in Hradec Králové, Sokolská 581, 50005 Hradec Králové, Czech Republic.
- 6. Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 08 Prague, Czech Republic.
- 7. Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic.
- 8. Institute of Health Economics and Technology Assessment (iHETA), Vaclavska 316/12, 120 00 Prague, Czech Republic.
- 9. Institute of Health Economics and Technology Assessment (iHETA), Vaclavska 316/12, 120 00 Prague, Czech Republic. Faculty of Medicine, Masaryk University, Department of Pharmacology, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 10. Institute of Biostatistics and Analyses, Ltd., Poštovská 68/3, 602 00 Brno, Czech Republic.
- 11. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59 Prague, Czech Republic.
Description
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
Notes
Files
577805.pdf
Files
(1.1 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:3c02d772721c555d3027c5dd74f6b91d
|
1.1 MB | Preview Download |